Newcastle disease virus: A promising agent for tumour immunotherapy

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 8, 2012, Pages 725-730

  Zhao, Lixiang ^a   Liu, Haiyan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Adaptive immune response; Immune regulation; Immunotherapy; Innate immune response; Malignant tumour; Newcastle disease virus; Oncolytic; Reverse genetics

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; ONCOLYTIC PARAMYXOVIRUS; PV 701; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; COLON CARCINOMA; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; FIBROSARCOMA; GENETIC RECOMBINATION; GLIOBLASTOMA; HUMAN; INNATE IMMUNITY; LIVER CELL CARCINOMA; MELANOMA; METASTASIS; NATURAL KILLER CELL; NEUROBLASTOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; REVIEW; T LYMPHOCYTE; TUMOR CELL; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84864316905     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05662.x     Document Type: Review

References (58)

1. Reed JC. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999; 17: 2941-53.
2. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-95.
3. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005; 26: 263-70.
4. Guinn BA, Mulherkar R. International progress in cancer gene therapy. Cancer Gene Ther. 2008; 15: 765-75.
5. Sinkovics J, Horvatz J. New developments in the virus therapy of cancer: A historical review. Intervirology 1993; 36: 193-214.
6. Ring CJA. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 2002; 83: 491-502.
7. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-6.
8. Longo SL, Griffith C, Glass A, Shillitoe EJ, Post DE. Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter. Cancer Gene Ther. 2011; 18: 123-34.
9. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin's disease after measles. Lancet 1981; 1: 1112.
10. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated ras pathway. Science 1998; 282: 1332-4.
11. Rommelaere J, Tattershall P. Oncosuppression by parvoviruses. In: Tijssen P (ed.). Handbook of Parvoviruses. CRC Press, Boca Raton. 1990; 41-57.
12. Stojdl DF, Lichty B, Knowles B et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000; 6: 821-5.
13. Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukaemia. A preliminary report. N. Engl. J. Med. 1964; 271: 645-51.
14. Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18: 863-8.
15. ®). Available from: (accessed 17 March 2010).
16. Nemunaitis J. Live viruses in cancer treatment. Oncology 2002; 16: 1483-92.
17. Aghi M, Martzua RL. Oncolytic viral therapies: The clinical experience. Oncogene 2005; 24: 7802-15.
18. Chlichlia K, Schirrmacher V, Sandaltzopoulos R. Cancer immunotherapy: Battling tumors with gene vaccines. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents 2005; 4: 353-65.
19. Schirrmacher V. T cell mediated immunotherapy of metastases: State of the art in 2005. Expert Opin. Biol. Ther. 2005; 4: 1051-68.
20. Steward M, Vipond IB, Millar NS, Emmerson PT RNA editing in Newcastle disease virus. J. Gen. Virol. 1993; 74: 2539-47.
21. Romer-Oberdorfer A, Werner O, Veits J, Mebatsion T, Mettenleiter TC. Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity. J. Gen. Virol. 2003; 84: 3121-9.
22. Bar-Eli N, Giloh H, Schlesinger M, Zakay-Rones Z. Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J. Cancer Res. Clin. Oncol. 1996; 122: 409-15.
23. Reichard KW, Lorence RM, Cascino CJ et al. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 1992; 52: 448-53.
24. Tzadok-David Y, Metzkin-Eizenberg M, Zakay-Rones Z. The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J. Cancer Res. Clin. Oncol. 1995; 121: 169-74.
25. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999; 6: 63-73.
26. Fournier P, Zeng J, Schirrmacher V. Two ways to induce innate immune responses in human PBMCs. Paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. Int. J. Oncol. 2003; 23: 673-80.
27. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR. Structure and function. J. Interferon Cytokine Res. 1997; 17: 503-24.
28. Kato H, Sato S, Yoneyama M et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28.
29. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004; 4: 499-511.
30. Janke M, Peeters B, de Leeuw O et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 2007; 14: 1639-49.
31. Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int. J. Cancer 1986; 37: 569-77.
32. Schirrmacher V, Heicappell R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti tumor immunity. Clin. Exp. Metastasis 1987; 5: 147-56.
33. Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol. 2004; 22: 4272-81.
34. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: Anti-tumor effects of local or systemic administration. Cancer Lett. 2001; 172: 27-36.
35. Lorence RM, Reichard KW, Katubig BB et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl Cancer Inst. 1994; 86: 1228-33.
36. Csatary LK, Csatary C, Gosztonyi G et al. Promising MTH-68/H oncolytic Newcastle disease virus therapy in human high grade gliomas. In: Yang AV (ed.). Focus on Brain Cancer Research. Nova Science Publishers, New York. 2006; 69-82.
37. Lorence RM, Pecora AL, Major PP et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 2003; 5: 618-24.
38. Schirrmacher V, Griesbach A, Ahlert T. Anti-tumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int. J. Oncol. 2001; 18: 945-52.
39. Young LS, Dawson CW, Eliopoulos AG. Viruses and apoptosis. Br. Med. Bull. 1997; 53: 509-21.
40. Fábián Z, Csatary M, Szeberényi J, Csatary LK. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J. Virol. 2007; 81: 2817-30.
41. Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 2006; 80: 7522-34.
42. Zorn U, Dallman I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother. 1994; 9: 225-35.
43. Batliwalla FM, Bateman BA, Serrano D et al.15-year follow-up of AJCC stage malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol. Med. 1998; 4: 783-94.
44. Washburn B, Weigand MA, Grosse-Wilde A et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J. Immunol. 2003; 170: 1814-21.
45. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int. J. Oncol. 2002; 21: 685-94.
46. Schild HJ, von Hoegen P, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor specific T cell response as a result of CD4 + and CD8 + immune T cell cooperation. Cancer Immunol. Immunother. 1988; 28: 22-8.
47. Termeer CC, Schirrmacher V, Bröcker EB. Newcastle-disease-virus infection induces a B7-1/B7-2 independent T-cell-costimulatory activity in human melanoma cells. Cancer Gene Ther. 2000; 7: 316-23.
48. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int. J. Oncol. 2002; 21: 85-93.
49. Roberts A, Rose JK. Recovery of negative-strand RNA viruses from plasmid DNAs: A positive approach revitalizes a negative field. Virology 1998; 247: 1-6.
50. Peeters BPH, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA. Evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 1999; 73: 5001-9.
51. Vigil A, Park MS, Martinez O et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007; 67: 8285-92.
52. Zamarin D, Vigil A, Kelly K, García-Sastre A, Fong Y. Genetically-engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 2009; 16: 796-804.
53. Altomonte J, Marozin S, Schmid RM, Ebert O. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 2010; 18: 275-84.
54. Zamarin D, Martinez-Sobbrido L, Kelly K et al. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol. Ther. 2009; 17: 697-706.
55. Pühler F, Willuda J, Puhlmann J, Mumberg D, Römer-Oberdörfer A, Beier R. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther. 2008; 15: 371-83.
56. Zhao H, Janke M, Fournier P, Schirrmacher V. Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res. 2008; 136: 75-80.
57. Janke M, Peeters B, Zhao H et al. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int. J. Oncol. 2008; 33: 823-32.
58. Vigil A, Martinez O, Chua MA, García-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 2008; 16: 1883-90.